Profusa, Inc. (PFSA)
NASDAQ: PFSA · Real-Time Price · USD
0.3084
+0.0115 (3.87%)
At close: Oct 1, 2025, 4:00 PM EDT
0.3257
+0.0173 (5.61%)
After-hours: Oct 1, 2025, 5:27 PM EDT
Company Description
Profusa, Inc. develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States.
The company offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery.
It also researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid.
Profusa, Inc. is based in Berkeley, California.
Profusa, Inc.
| Country | United States |
| Founded | 2009 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Ben Hwang |
Contact Details
Address: 626 Bancroft Way, Suite A Berkeley, California 94710 United States | |
| Phone | 925 997 6925 |
| Website | profusa.com |
Stock Details
| Ticker Symbol | PFSA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001859807 |
| Employer ID | 86-3437271 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ben Chung-Bin Hwang Ph.D. | Chief Executive Officer and Chairman |
| William McMillan | Co-founder, Chief Scientific Officer and Head of Research |
| Fred S. Knechtel | Chief Financial Officer and Director |
| David Icke | Head of Digital Health Business |
| Sean Givens | Head of Government Business |
| Phil Constantinou | Head of Software and Data Science |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 26, 2025 | EFFECT | Notice of Effectiveness |
| Sep 26, 2025 | 424B3 | Prospectus |
| Sep 23, 2025 | DEF 14A | Other definitive proxy statements |
| Sep 17, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Sep 16, 2025 | 8-K | Current Report |
| Sep 10, 2025 | PRE 14A | Other preliminary proxy statements |
| Sep 4, 2025 | 8-K | Current Report |
| Aug 29, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Aug 26, 2025 | 8-K | Current Report |
| Aug 25, 2025 | EFFECT | Notice of Effectiveness |